• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病(IBD)患者更喜欢口服片剂,而不是其他给药方式。

Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration.

机构信息

Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.

出版信息

Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1091-1096. doi: 10.1080/17474124.2021.1898944. Epub 2021 Mar 10.

DOI:10.1080/17474124.2021.1898944
PMID:33653185
Abstract

: With increasing treatment choices for inflammatory bowel disease (IBD), patients' preferences should be considered to limit non-adherence. We explored patients' preferences for route, form and frequency of medication administration, and factors influencing these choices.: Patients rated acceptability of different forms of medication on 10-point Likert scales and preferences for highest acceptable frequency.: Of 298 patients significantly more found tablets (91%) to be highly acceptable compared to granules (64%), infusions (33%) and subcutaneous injections (34%; p < 0.0001). The acceptable frequency for tablets was considered as daily by 63.5% and several times daily by 32.3%. Participants preferred nurse delivered over self-administered injections (median score 8 vs 5, p < 0.0001) and hospital-based infusions over infusions at home (median score 7 vs 5, p = 0.001). Patients with previous or current anti-TNF exposure were more accepting of self-administered injections (50.5% vs 23.3% anti-TNF naive; p < 0.001), more accepting of home based infusions (43.7% vs 28.0%; p = 0.001) and more accepting of hospital-based infusions (57.2% vs 37.8%; p = 0.02).: Most patients with IBD prefer tablets. Those patients who already experienced biological agents, had a high level of acceptance for subcutaneous and intravenous forms of medication.

摘要

:随着炎症性肠病(IBD)治疗选择的增加,应考虑患者的偏好以限制不依从。我们探讨了患者对药物给药途径、形式和频率的偏好,以及影响这些选择的因素。:患者对不同药物形式的可接受性进行 10 分李克特量表评分,并对最高可接受频率的药物进行偏好评估。:在 298 名患者中,明显更多的患者(91%)认为片剂比颗粒剂(64%)、输注剂(33%)和皮下注射剂(34%)更易接受(p < 0.0001)。63.5%的患者认为片剂的可接受频率为每天,32.3%的患者认为可接受的频率为每天多次。参与者更喜欢护士给药而不是自行注射(中位数评分 8 对 5,p < 0.0001),更喜欢医院内输注而不是在家输注(中位数评分 7 对 5,p = 0.001)。有既往或当前抗 TNF 暴露的患者对自我管理注射的接受程度更高(50.5%对 TNF 初治患者的 23.3%;p < 0.001),对家庭基础输注的接受程度更高(43.7%对 28.0%;p = 0.001),对医院内输注的接受程度更高(57.2%对 37.8%;p = 0.02)。:大多数 IBD 患者更喜欢片剂。那些已经使用过生物制剂的患者,对皮下和静脉形式的药物具有更高的接受度。

相似文献

1
Patients with inflammatory bowel disease (IBD) prefer oral tablets over other modes of medicine administration.炎症性肠病(IBD)患者更喜欢口服片剂,而不是其他给药方式。
Expert Rev Gastroenterol Hepatol. 2021 Sep;15(9):1091-1096. doi: 10.1080/17474124.2021.1898944. Epub 2021 Mar 10.
2
How do patients with inflammatory bowel disease want their biological therapy administered?炎症性肠病患者希望如何接受生物治疗?
BMC Gastroenterol. 2010 Jan 10;10:1. doi: 10.1186/1471-230X-10-1.
3
Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.医生应为炎症性肠病患者的抗TNF治疗提供共同决策。
J Korean Med Sci. 2017 Jan;32(1):85-94. doi: 10.3346/jkms.2017.32.1.85.
4
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study.炎症性肠病患者治疗维持方案的比较可接受性:全国性ACCEPT2研究结果
Inflamm Bowel Dis. 2023 Apr 3;29(4):579-588. doi: 10.1093/ibd/izac119.
5
FACTORS ASSOCIATED WITH PATIENT´S PREFERENCE IN CHOOSING THEIR THERAPY FOR INFLAMMATORY BOWEL DISEASE IN BRAZIL.巴西炎症性肠病患者选择治疗方法的偏好因素。
Arq Gastroenterol. 2020 Sep-Dec;57(4):491-497. doi: 10.1590/S0004-2803.202000000-86.
6
Predicting Pre-emptive Discussions of Biologic Treatment: Results from an Openness and Preference Survey of Inflammatory Bowel Disease Patients and Their Prescribers.预测生物治疗的前瞻性讨论:炎症性肠病患者及其处方医生的开放性和偏好调查结果
Adv Ther. 2017 Jun;34(6):1398-1410. doi: 10.1007/s12325-017-0545-4. Epub 2017 May 8.
7
Quality of life related to oral, subcutaneous, and intravenous biologic treatment of inflammatory bowel disease: a time trade-off study.炎症性肠病的口服、皮下及静脉生物治疗相关的生活质量:一项时间权衡研究
Eur J Gastroenterol Hepatol. 2018 Feb;30(2):174-180. doi: 10.1097/MEG.0000000000001031.
8
Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.家庭输注英夫利昔单抗与炎症性肠病的不良结局相关,且无成本节约。
Am J Gastroenterol. 2020 Oct;115(10):1698-1706. doi: 10.14309/ajg.0000000000000750.
9
Inflammatory Bowel Disease Patients' Preferences for Subcutaneous versus Intravenous Therapies: A Mixed-Methods Study.炎症性肠病患者对皮下和静脉治疗的偏好:一项混合方法研究。
Dig Dis. 2023;41(3):412-421. doi: 10.1159/000528586. Epub 2022 Dec 7.
10
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients.炎症性肠病患者从静脉注射生物疗法转换为皮下生物疗法:一项患者在线调查
Indian J Gastroenterol. 2024 Feb;43(1):215-225. doi: 10.1007/s12664-023-01500-2. Epub 2024 Jan 20.

引用本文的文献

1
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries.炎症性肠病患者对治疗属性的偏好:五个非西方国家患者的离散选择实验
Adv Ther. 2025 Jun 17. doi: 10.1007/s12325-025-03249-w.
2
Oral Peptide Therapeutics as an Emerging Treatment Modality in Immune-Mediated Inflammatory Diseases: A Narrative Review.口服肽疗法作为免疫介导炎症性疾病的一种新兴治疗方式:一项叙述性综述。
Adv Ther. 2025 May 29. doi: 10.1007/s12325-025-03213-8.
3
Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling.
构建一种蛋白酶稳定的口服单域抗体以抑制白细胞介素-23信号传导。
Proc Natl Acad Sci U S A. 2025 Jun 3;122(22):e2501635122. doi: 10.1073/pnas.2501635122. Epub 2025 May 28.
4
The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis.目前用于治疗溃疡性结肠炎的1-磷酸鞘氨醇受体调节剂
J Clin Med. 2025 May 15;14(10):3475. doi: 10.3390/jcm14103475.
5
Questionnaire Survey of Japanese Patients With Inflammatory Bowel Disease and Physicians on Shared Decision-Making in Advanced Therapy: A Web-Based PAIR Survey.日本炎症性肠病患者与医生关于晚期治疗共同决策的问卷调查:一项基于网络的配对调查
Crohns Colitis 360. 2025 Apr 9;7(2):otaf014. doi: 10.1093/crocol/otaf014. eCollection 2025 Apr.
6
Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease.在炎症性肠病管理中使用生物类似药加速抗TNF-α药物的早期获取。
J Clin Med. 2025 Feb 26;14(5):1561. doi: 10.3390/jcm14051561.
7
Paradigm Shift in Inflammatory Bowel Disease Management: Precision Medicine, Artificial Intelligence, and Emerging Therapies.炎症性肠病管理的范式转变:精准医学、人工智能及新兴疗法
J Clin Med. 2025 Feb 25;14(5):1536. doi: 10.3390/jcm14051536.
8
Medication Non-Adherence in Inflammatory Bowel Disease: A Systematic Review Identifying Risk Factors and Opportunities for Intervention.炎症性肠病中的药物治疗不依从性:一项识别风险因素和干预机会的系统评价
Pharmacy (Basel). 2025 Feb 7;13(1):21. doi: 10.3390/pharmacy13010021.
9
Designing for medication adherence in inflammatory bowel disease: multi-disciplinary approaches for self-administrable biotherapeutics.炎症性肠病药物依从性的设计:可自我给药生物疗法的多学科方法。
EClinicalMedicine. 2024 Oct 10;77:102850. doi: 10.1016/j.eclinm.2024.102850. eCollection 2024 Nov.
10
Patient and Healthcare Professional Satisfaction, Acceptability, and Preference Experiences With Mirikizumab Administration for Ulcerative Colitis: An International Survey.溃疡性结肠炎患者及医疗保健专业人员对使用mirikizumab治疗的满意度、可接受性和偏好体验:一项国际调查。
Crohns Colitis 360. 2024 Oct 4;6(4):otae054. doi: 10.1093/crocol/otae054. eCollection 2024 Oct.